Surgical Oncology
Volume 19, Issue 2 , Pages e57-e70 , June 2010

Cervical lymph node dissection in papillary thyroid cancer: Current trends, persisting controversies, and unclarified uncertainties

,Accepted 1 April 2009.

References 

  1. Gosnell JE, Clark OH. Surgical approaches to thyroid tumors. Endocrinol Metab Clin North Am. 2008;37:437–455
  2. Hundahl SA, Cady B, Cunningham MP, et al. Initial results from a prospective cohort study of 5583 cases of thyroid carcinoma treated in the United States during 1996. U.S. and German Thyroid Cancer Study Group. Cancer. 2000;89:202–217
  3. Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun Mj. Cancer statistics. CA Cancer J Clin. 2007;57:43–66
  4. Cooper DS, Doherty GM, Haugen BR, Kloos RT, Lee SL, Mandel SJ, et al. Management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid. 2006;16:109–142
  5. Tisell LE, Nilsson B, Molne J, Hansson G, Fjalling M, Jansson S, et al. Improved survival of patients with papillary thyroid cancer after surgical microdissection. World J Surg. 1996;20:854–859
  6. Kupferman ME, Patterson M, Mandel SJ, LiVolsi V, Weber RS. Patterns of lateral neck metastasis in papillary thyroid carcinoma. Arch Otolaryngol Head Neck Surg. 2004;130:857–860
  7. Sivanandan R, Soo KC. Pattern of cervical lymph node metastases from papillary carcinoma of the thyroid. Br J Surg. 2001;88:1241–1244
  8. Shaha AR, Shah JP, Loree TR. Patterns of nodal and distant metastasis based on histologic varieties in differentiated carcinoma of the thyroid. Am J Surg. 1996;172:692–694
  9. Kelemen PR, Van Herle AJ, Giuliano AE. Sentinel lymphadenectomy in thyroid malignant neoplasms. Arch Surg. 1998;133:288–292
  10. Dixon E, McKinnon JG, Pasieka JL. Feasibility of sentinel lymph node biopsy and lymphatic mapping in nodular thyroid neoplasms. World J Surg. 2000;24:1396–1401
  11. Fukui Y, Yamakawa T, Taniki T, Numoto S, Miki H, Monden Y. Sentinel lymph node biopsy in patients with papillary thyroid carcinoma. Cancer. 2001;92:2868–2874
  12. Arch-Ferrer J, Velazquez D, Fajardo R, Gamboa-Dominguez A, Herrera MF. Accuracy of sentinel lymph node in papillary thyroid carcinoma. Surgery. 2001;130:907–913
  13. Pelizzo MR, Boschin IM, Toniato A, Bernante P, Piotto A, Rinaldo A, et al. The sentinel node procedure with Patent Blue V dye in the surgical treatment of papillary thyroid carcinoma. Acta Otolaryngol. 2001;121:421–424
  14. Dzodic R, Markovic I, Inic M, Jokic N, Djurisic I, Zegarac M, et al. Sentinel lymph node biopsy may be used to support the decision to perform modified radical neck dissection in differentiated thyroid carcinoma. World J Surg. 2006;30:841–846
  15. Wada N, Duh QY, Sugino K, Iwasaki H, Kameyama K, Mimura T, et al. Lymph node metastasis from 259 papillary thyroid microcarcinomas: frequency, pattern of occurrence and recurrence, and optimal strategy for neck dissection. Ann Surg. 2003;237:399–407
  16. Sakorafas GH, Giotakis J, Stafyla V. Papillary thyroid microcarcinoma: a surgical perspective. Cancer Treat Rev. 2005;31:423–438
  17. Hubert JP, Kiernam PD, Beahrs OH. Occult papillary carcinoma of the thyroid. Arch Surg. 1980;115:394–396
  18. Grant CS, van Heerden JA. Papillary thyroid microcarcinoma: a study of 535 cases observed in a 50-year period. Surgery. 1992;112:1139–1145
  19. Chow SM, Lay SC, Chan JK, Au SK, Yau S, Lau WH. Papillary microcarcinoma of the thyroid—prognostic significance of lymph node metastasis and multifocality. Cancer. 2003;98:31–40
  20. Ito Y, Tomoda C, Uruno T, Takamura Y, Miya A, Kobayashi K, et al. Clinical significance of metastasis to the central compartment from papillary microcarcinoma of the thyroid. World J Surg. 2006;30:91–99
  21. Gulben K, Berberoglu U, Celen O, Mersin HH. Incidental papillary microcarcinoma of the thyroid-factors affecting lymph node metastasis. Langenbecks Arch Surg. 2008;393:25–29
  22. Lee SH, Lee SS, Jin SM, Kim JH, Rho YS. Predictive factors for central compartment lymph node metastasis in thyroid papillary microcarcinoma. Laryngoscope. 2008;118:659–662
  23. Seigel RJ. Surgical pathology of lymph nodes in cancer staging: routine and specialized techniques. Surg Oncol Clin N Am. 1996;5(1):25–31
  24. Qubain SW, Nakano S, Baba M, Takao S, Aikou T. Distribution of lymph node micrometastasis in pN0 well-differentiated thyroid carcinoma. Surgery. 2002;131:249–256
  25. Cranshaw IM, Carnaille B. Micrometastases in thyroid cancer. An important finding?. Surg Oncol. 2008;17:253–258
  26. Cranshaw IM, Jany T, Arnalsteen L, Pattou F, Carnaille B. Significance of lymph node micrometastases in papillary thyroid carcinoma. ANZ J Surg. 2007;77(Suppl. 1):A21
  27. Shaha AR, Shah J, Loree TR. Patterns of failure in differentiated carcinoma of the thyroid based on risk groups. Head Neck. 1998;20:26–30
  28. Grebe SK, Hay ID. Thyroid cancer nodal metastases: biologic significance and therapeutic considerations. Surg Oncol Clin N Am. 1996;5:43–63
  29. Harwood J, Clark OH, Dunphy JE. Significance of lymph node metastasis in differentiated thyroid cancer. Am J Surg. 1978;136:107–112
  30. Mazzaferri EL, Young RL. Papillary thyroid carcinoma: a 10 year follow-up report of the impact of therapy in 576 patients. Am J Med. 1981;70:511–518
  31. McHenry CR, Rosen IB, Walfish PG. Prospective management of nodal metastases in differentiated thyroid cancer. Am J Surg. 1991;162:353–356
  32. McCohaney WM, Hay ID, Woolner LB, van Heerden JA, Taylor WF. Papillary thyroid cancer treated at the Mayo Clinic, 1946 through 1970: initial manifestations, pathologic finding, therapy, and outcome. Mayo Clin Proc. 1986;61:978–996
  33. Mazzaferri EL. Papillary thyroid carcinoma: factors influencing prognosis and current therapy. Semin Oncol. 1987;14:315–332
  34. Akslen LA. Prognostic importance of histologic grading in papillary thyroid carcinoma. Cancer. 1993;72:2680–2685
  35. Wada N, Suganuma N, Nakayama H, Masudo K, Rino Y, Masuda M, et al. Microscopic regional lymph node status in papillary thyroid carcinoma with and without lymphadenopathy and its relation to outcomes. Langenbecks Arch Surg. 2007;392:417–422
  36. Hughes CJ, Shaha AR, Shah JP, Loree TR. Impact of lymph node metastasis in differentiated carcinoma of the thyroid: a matched-pair analysis. Head Neck. 1996;18:127–132
  37. Sugino K, Kure Y, Iwasaki H, Ozaki O, Mimura T, Matsumoto A, et al. Metastases to the regional lymph nodes, lymph node recurrence, and distant metastases in nonadvanced papillary thyroid carcinoma. Surg Today. 1995;25:324–328
  38. Cady B, Rossi R. An expanded view of the risk-group definition in differentiated thyroid carcinoma. Surgery. 1988;104:947–953
  39. Mazzeferri EL, Jhiang SM. Long-term impact of initial surgical and medical therapy on papillary and follicular thyroid cancer. Am J Med. 1994;97:418–428
  40. Hay ID, Bergstralh EJ, Goellner JR, Ebersold JR, Grant CS. Predicting outcome in papillary thyroid carcinoma: development of a reliable prognostic scoring system in a cohort of 1779 patients surgically treated at one institution during 1940 through 1989. Surgery. 1993;114:1050–1058
  41. Kukkonen ST, Haapiainen RK, Rranssila KO, Sivula AH. Papillary thyroid carcinoma: the new, age-related TNM classification system in a retrospective analysis of 199 patients. World J Surg. 1990;14:837–842
  42. Ito Y, Higashiyama T, Takamura T, Miya A, Kobayashi K, Matsuzuka F, et al. Risk factors for recurrence to the lymph node in papillary thyroid carcinoma patients without preoperatively detectable lateral node metastasis: validity of prophylactic modified radical neck dissection. World J Surg. 2007;31:2085–2091
  43. Lundgren CI, Hall P, Dickman PW, Zedenius J. Clinically significant prognostic factors for differentiated thyroid carcinoma: a population-based, nested case-control study. Cancer. 2006;106:524–531
  44. Scheumann GF, Gimm O, Wegener G, Hundeshagen H, Dralle H. Prognostic significance and surgical management of locoregional lymph node metastases in papillary thyroid cancer. World J Surg. 1994;18:559–568
  45. Ohshima A, Yamashita H, Noguchi S, Uchino S, Watanabe S, Toda M, et al. Indications for bilateral modified radical neck dissection in patients with papillary carcinoma of the thyroid. Arch Surg. 2000;135:1194–1199
  46. Yamashita H, Noguchi S, Murakami N, Kawamoto H, Watanabe S. Extracapsular invasion of lymph node metastasis is an indicator of distant metastasis and poor prognosis in patients with thyroid papillary carcinoma. Cancer. 1997;80(12):2268–2272
  47. Rossi RL, Cady B, Silverman ML, Wool MS, Horner TA. Current trends of conservative surgery for differentiated thyroid carcinoma. World J Surg. 1986;10:612–622
  48. DeGroot LJ, Kaplan EL, McCormick M, Straus FH. Natural history, treatment, and course of papillary thyroid carcinoma. J Clin Endocrinol Metab. 1990;71:414–424
  49. Byar DP, Green SB, Dor P, Williams ED, Colon J, van Gilse HA, et al. A prognostic index for thyroid carcinoma: a study of the E.O.R.T.C. thyroid cancer cooperative group. Eur J Cancer. 1979;15:1033–1041
  50. Bhattacharyya N. Surgical treatment of cervical nodal metastases in patients with papillary thyroid carcinoma. Arch Otolaryngol Head Neck Surg. 2003;129:1101–1104
  51. Bhattacharyya N. A population-based analysis of survival factors in differentiated and medullary thyroid carcinoma. Otolaryngol Head Neck Surg. 2003;128:115–123
  52. Sugitani I, Kasai N, Fujimoto Y, Yanagisawa A. A novel classification system for patients with PTC: addition of the new variables of large (3cm or greater) nodal metastases and reclassification during the follow-up period. Surgery. 2004;135:139–148
  53. Noguchi S, Murakami N, Yamashita H, Toda M, Kawamoto H. Papillary thyroid carcinoma: modified radical neck dissection improves prognosis. Arch Surg. 1998;133:276–281
  54. Simon D, Goretzki PE, Witte J, Roher HD. Incidence of regional recurrence guiding radicality in differentiated thyroid carcinoma. World J Surg. 1996;20:860–866
  55. Lee YS, Kim SW, Kim SW, et al. Extent of routine central lymph node dissection with small papillary thyroid carcinoma. World J Surg. 2007;31:1954–1959
  56. Esnaola NF, Cantor SB, Sherman SI, Lee JE, Evans DB. Optimal treatment strategy in patients with papillary thyroid cancer: a decision analysis. Surgery. 2001;130:921–930
  57. Grubbs EG, Rich TA, Li G, Sturgis EM, Younes MN, Myers JN, et al. Recent advances in thyroid cancer. Curr Probl Surg. 2008;45:156–250
  58. Grodski S, Cornford L, Sywak M, Sidhu S, Delbridge L. Routine level VI lymph node dissection for papillary thyroid cancer: surgical technique. ANZ J Surg. 2007;77:203–208
  59. Ying M, Ahuja A. Sonography of neck lymph nodes. Part I: normal lymph nodes. Clin Radiol. 2003;58:351–358
  60. Fish SA, Langer JE, Mandel SJ. Sonographic imaging of thyroid nodules and cervical lymph nodes. Endocrinol Metab Clin North Am. 2008;37:401–417
  61. Som PM, Curtin HD, Mancuso AA. An imaging-based classification for the cervical nodes designed as an adjunct to recent clinically based nodal classifications. Arch Otolaryngol Head Neck Surg. 1999;125:388–396
  62. Robbins KT, Clayman G, Levine PA, Medina J, Sessions R, Shaha A, et al. Neck dissection classification update: revisions proposed by the American Head and Neck Society and the American Academy of Otolaryngology – Head and Neck Surgery. Arch Otolaryngol Head Neck Surg. 2002;128:751–758
  63. Shaha AR. Management of the neck in thyroid cancer. Otolaryngol Clin North Am. 1998;31:823–831
  64. Roh JL, Kim JM, Park CI. Lateral cervical lymph node metastases from papillary thyroid carcinoma: pattern of nodal metastases and optimal strategy for neck dissection. Ann Surg Oncol. 2008;15:1177–1182
  65. Lee J, Sung TY, Nam KH, Chung WY, Soh EY, Park CS. Is level IIb lymph node dissection always necessary in N1b papillary thyroid carcinoma patients?. World J Surg. 2008;32:716–721
  66. Shah JP. Cervical lymph node metastases—diagnostic, therapeutic and prognostic implications. Oncology. 1990;4:61–69
  67. Caron NR, Tan YY, Ogivlie JB, Triponez F, Reiff ES, Kebebew E, et al. Selective modified radical neck dissection for papillary thyroid cancer—is level I, II and V dissection always necessary?. World J Surg. 2006;30:833–840
  68. Gimm O, Rath FW, Dralle H. Pattern of lymph node metastases in papillary thyroid carcinoma. Br J Surg. 1998;85:252–254
  69. Roh JL, Park JY, Park CI. Total thyroidectomy plus neck dissection in differentiated papillary thyroid carcinoma patients: pattern of nodal metastasis, morbidity, recurrence, and postoperative levels of serum parathyroid hormone. Ann Surg. 2007;245:604–610
  70. Machens A, Hinze R, Thomusch O, Dralle H. Pattern of nodal metastasis for primary and reoperative thyroid cancer. World J Surg. 2002;26:22–28
  71. Noguchi S, Noguchi A, Murakami N. Papillary carcinoma of the thyroid. I. Developing pattern of metastasis. Cancer. 1970;26:1053–1060
  72. Mirallie E, Visset J, Sagan C, Hamy A, Le Bodic MF, Paineau J. Localization of cervical node metastasis of papillary thyroid carcinoma. World J Surg. 1999;23:970–974
  73. Machens A, Holzhausen HJ, Dralle H. Skip metastases in thyroid cancer leaping the central lymph node compartment. Arch Surg. 2004;139:43–45
  74. Robbins KT, Atkinson J, Byers RM, Cohen JI, Lavertu P, Pellitteri P. The use and misuse of neck dissection for head and neck cancer. J Am Coll Surg. 2001;193:91–102
  75. Byers RM. Neck dissection: concepts, controversies, and technique. Semin Surg Oncol. 1991;7:9–13
  76. Shaha AR. Complications of neck dissection for thyroid cancer. Ann Surg Oncol. 2008;15:397–399
  77. Musacchio MJ, Kim AW, Vijungco JD, Prinz RA. Greater local recurrence occurs with ‘berry picking’ than neck dissection in thyroid cancer. Am Surg. 2003;69:191–196
  78. Palazzo FF, Gosnell J, Savio R, Reeve TS, Sidhu SB, Sywak MS, et al. Lymphadenectomy for papillary thyroid cancer: changes in practice over four decades. Eur J Surg Oncol. 2006;32:340–344
  79. Tuttle RM, Loboeuf R, Martorella AJ. Papillary thyroid cancer: monitoring and therapy. Endocrinol Metab Clin North Am. 2007;36:753–778
  80. Noguchi M, Kumaki T, Taniya T, Miyazaki I. Bilateral cervical lymph node metastases in well differentiated thyroid cancer. Arch Surg. 1990;125:804–806
  81. Henry JF, Gramatica L, Denizot A, Kvachenyuk A, Puccini M, Defechereux T. Morbidity of prophylactic lymph node dissection in the central neck area in patients with papillary thyroid carcinoma. Langenbecks Arch Surg. 1998;383:167–169
  82. Noguchi M, Earashi M, Kitagawa H, Ohta N, Thomas M, Miyazaki I, et al. Papillary thyroid cancer and its surgical management. J Surg Oncol. 1992;49:140–149
  83. Thyroid carcinoma. Available from: Clinical practice guidelines in oncology. vol 2007. National Comprehensive Cancer Network, Inc; 2007;http://www.nccn.rg/professionals/physician_gls/PRF/thyroid.pdfVersion 2.2007
  84. Pacini F, Schlumberger M, Dralle H, Ilisea R, Smith Y, Viersinga V. European consensus for the management of patients with differentiated thyroid carcinoma of the follicular epithelium. Eur J Endocrinol. 2006;154:787–803
  85. Shimamoto K, Satake H, Sawaki A, Ishigaki T, Funahashi H, Imai T. Preoperative staging of thyroid papillary carcinoma with ultrasonography. Eur J Radiol. 1998;29:4–10
  86. Solorzano CC, Carneiro DM, Ramirez M, Lee TM, Irvin GL. Surgeon-performed ultrasound in the management of thyroid malignancy. Am Surg. 2004;70:576–582
  87. Kupferman ME, Weinstock YE, Santillan AA, Mishra A, Roberts D, Clayman GL, et al. Thyroid. In: Townsend: Sabiston textbook of Surgery. 18th ed. Philadelphia: Elsevier-Saunders; 2007;p. 707–745
  88. Kupferman ME, Weinstock EY, Santillan AA, et al. Predictors of level V metastasis in well-differentiated thyroid cancer. Head Neck. 2008;30:1469–1474
  89. BTA . British Thyroid Association and Royal College of Physicians: guidelines for the management of thyroid cancer in adults. Available at: www.british-thyroid-association.org2002;
  90. Roher HD, Simon D, Goretzki PE. Guidelines in oncologic surgery – malignant thyroid tumours. Lang Arch Chir Kongressbd. 1997;114:142–145
  91. Sywak M, Cornford L, Roach P, Stalberg P, Sidhu S, Delbridge L. Routine ipsilateral level VI lymphadenectomy reduces postoperative thyroglobulin levels in papillary thyroid cancer. Surgery. 2006;140:1000–1005
  92. Son YI, Jeong HS, Baek CH, Chung MK, Ryu J, Chung JH, et al. ThyroidCarcinomaTaskForce. AACE/AAES medical/surgical guidelines for clinical practice: management of thyroid carcinoma. American Association of Clinical Endocrinologists. American College of Endocrinology. Endocr Pract. 2001;7:202–220
  93. National Comprehensive Cancer Network . NCCN clinical practice guidelines in oncology. Thyroid carcinoma. Version 2. Available at: http://www.nccn.org/professionals/physician_gls/PDF/thyroid.pdf2007;
  94. Son Y-I, Jeong H-S, Baek C-H, et al. Extent of prophylactic lymph node dissection in the central neck area of the patients with papillary thyroid carcinoma: comparison of limited versus comprehensive lymph node dissection in a 2-year safety study. Ann Surg Oncol. 2008;15:2020–2026
  95. Kim JM, Kim TY, Kim WB, Gong G, Kim SC, Hong SJ, et al. Lymphovascular invasion is associated with lateral cervical lymph node metastasis in papillary thyroid carcinoma. Laryngoscope. 2006;116:2081–2085
  96. Roh JL, Kim JM, Park C. Central cervical nodal metastasis from papillary thyroid microcarcinoma: pattern and factors predictive of nodal metastasis. Ann Surg Oncol. 2008;15:2482–2486
  97. Shindo M, Wu JC, Park EE, Tanzella F. The importance of central compartment elective lymph node excision in the staging and treatment of papillary thyroid cancer. Arch Otolaryngol Head Neck Surg. 2006;132:650–654
  98. Cheah K, Arici C, Ituarte PH, Siperstein AE, Duh OY, Clark OH. Complications of neck dissection for thyroid cancer. World J Surg. 2002;26:1013–1016
  99. Dijkstra PU, van Wilgen PC, Buijs RP, Brendeke W, de Goede CJ, Kerst A, et al. Incidence of shoulder pain after neck dissection: a clinical explorative study for risk factors. Head Neck. 2001;23:947–953
  100. Cheng PT, Hao SP, Lin YH, Yeh AR. Objective comparison of shoulder dysfunction after three neck dissection techniques. Ann Otol Rhinol Laryngol. 2000;109:761–766
  101. Cappiello J, Piazza C, Giudice M, DeMaria G, Nicolai P. Shoulder disability after different selective neck dissections (levels II–IV versus levels II–V): a comparative study. Laryngoscope. 2005;115:259–263
  102. Kuntz AL, Weymuller EA. Impact of neck dissection on quality of life. Laryngoscope. 1999;109:1334–1338
  103. Scheumann GF, Seeliger H, Musholt TF, Gimm O, Wegener G, Dralle H, et al. Completion thyroidectomy in 131 patients with differentiated thyroid carcinoma. Eur J Surg. 1996;162:677–684
  104. Terrell JE, Welsh DE, Bradford CR, Chepeha DB, Esclamado RM, Hogikyan ND, et al. Pain, quality of life, and spinal accessory nerve status after neck dissection. Laryngoscope. 2000;110:620–626
  105. Inoue H, Nibu K, Saito M, Otsuki N, Ishida H, Onitsuka T, et al. Quality of life after neck dissection. Arch Otolaryngol Head Neck Surg. 2006;132:662–666
  106. van Wilgen CP, Dijkstra PU, van der Laan BF, Plukker JT, Roodenburg JL. Shoulder complaints after neck dissection; is the spinal accessory nerve involved?. Br J Oral Maxillofac Surg. 2003;41:7–11
  107. Sobol S, Jensen C, Sawyer W, Costiloe P, Thong N. Objective comparison of physical dysfunction after neck dissection. Am J Surg. 1985;150:503–509
  108. Miccoli P, Materazzi G, Berti P. Minimally invasive video-assisted lateral lymphadenectomy: a proposal. Surg Endosc. 2008;22:1131–1134
  109. Lombardi CP, Raffaelli M, Princi P, De Crea C, Bellantone R. Minimally invasive video-assisted functional lateral neck dissection for metastatic papillary thyroid carcinoma. Am J Surg. 2007;193:114–118
  110. Sakorafas GH, Peros G. Sentinel lymph node biopsy in breast cancer; what a clinician should know, a decade after its introduction in clinical practice. Eur J Cancer Care. 2007;16:318–321
  111. Ariyan CE, Coit DG. Clinical aspects of sentinel lymph node biopsy in melanoma. Sem Diagn Pathol. 2008;25:86–94
  112. Roh J-L, Park C. Sentinel lymph node biopsy as guidance for central neck dissection in patients with papillary thyroid carcinoma. Cancer. 2008;113:1527–1531
  113. Rubello D, Pelizzo MR, Al-Nahhas A, Salvatori M, O'Doherty MJ, Guiliano AE, et al. The role of sentinel lymph node biopsy in patients with differentiated thyroid carcinoma. Eur J Surg Oncol. 2006;32:917–921
  114. Pujol P, Daures JP, Nsakala N, Baldet L, Bringer J, Jaffiol C. Degree of thyrotropin suppression as a prognostic determinant in differentiated thyroid cancer. J Clin Endocrinol Metab. 1996;81:4318–4323
  115. McGriff NJ, Csako G, Gourgiotis L, Lori CG, Pucini F, Sarlis NJ. Effects of thyroid hormone suppression therapy on adverse clinical outcomes in thyroid cancer. Ann Med. 2002;34:554–564
  116. Biondi B, Filetti S, Schlumberger M. Thyroid-hormone therapy and thyroid cancer: a reassessment. Nat Clin Pract Endocrinol Metab. 2005;1(1):32–40
  117. Haugen BR, Pacini F, Reiners C, Schlumberger M, Ladenson PW, Sherman SI, et al. A comparison of recombinant human thyrotropin and thyroid hormone withdrawal for the detection of thyroid remnant or cancer. J Clin Endocrinol Metab. 1999;84:3877–3885
  118. Burmeister LA, Goumaz MO, Mariash CN, Oppenheimer JH. Levothyroxine dose requirements for thyrotropin suppression in the treatment of differentiated thyroid cancer. J Clin Endocrinol Metab. 1992;75:344–350
  119. Sun L, Davies TF, Blair HC, Abe E, Zaidi M. TSH and bone loss. Ann N Y Acad Sci. 2006;1068:309–318
  120. Sawin CT, Geller A, Wolf PA, Belanger AJ, Baker E, Bacharach P, et al. Low serum thyrotropin concentrations as a risk factor for atrial fibrillation in older persons. N Engl J Med. 1994;331:1249–1252
  121. Parle JV, Maisonneuve P, Sheppard MC, Boyle P, Franklyn JA. Prediction of all-cause and cardiovascular mortality in elderly people from one low-serum thyrotropin result: a 10-year cohort study. Lancet. 2001;358:861–865
  122. Surks MI, Ortiz E, Daniels GH, Sawin CT, Col NF, Cobin RH, et al. Subclinical thyroid disease: scientific review and guidelines for diagnosis and management. JAMA. 2004;291:228–238
  123. Tubiana M, Perez R, Parmentier C, Monnier JP. The survival of patients with thyroid cancers treated with radioactive iodine. Apropos of 147 cases followed up for more than 5 years. Presse Med. 1968;76:1999–2002
  124. Hay ID, Thompson GB, Grant CS, Bergstralh EJ, Dvorak CE, Gorman CA, et al. Papillary thyroid carcinoma managed at the Mayo Clinic during six decades (1940–1999): temporal trends in initial therapy and long-term outcome in 2444 consecutively treated patients. World J Surg. 2002;26:879–885
  125. Sawka AM, Thephamongkhol K, Brouwers M, Thabane L, Browman G, Gerstein HC. Clinical review 170: a systematic review and metaanalysis of the effectiveness of radioactive iodine remnant ablation for well-differentiated thyroid cancer. J Clin Endocrinol Metab. 2004;89:3668–3676
  126. Hay ID, McConahey WM, Goellner JR. Managing patients with papillary thyroid carcinoma: insights gained from the Mayo Clinic's experience of treating 2512 consecutive patients during 1940 through 2000. Trans Am Clin Climatol Assoc. 2002;113:241–260

PII: S0960-7404(09)00048-6

doi: 10.1016/j.suronc.2009.04.002

Surgical Oncology
Volume 19, Issue 2 , Pages e57-e70 , June 2010

Article Tools

* Image Usage & Resolution